Skip to Content

Smith & Nephew PLC ADR SNN

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Smith & Nephew Broadens Orthopedic Portfolio to Include Extremities; No Change to Our FVE

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

We expect Smith & Nephew’s integration of the extremities business from Integra LifeSciences to reinforce its narrow economic moat, but thus far, it adds little to our valuation as these products will account for roughly 2% of consolidated revenue. We interpret this acquisition through several lenses.

Read Full Analysis

Company Profile

Business Description

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and ENT technologies, and wound-care solutions. Slightly more than 40% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 27% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Contact
Hatters Lane, Building 5, Croxley Park
Watford, Hertfordshire, WD18 8YE, United Kingdom
T +44 1923477100
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Dec 31, 2014
Fiscal Year End Dec 31, 2020
Stock Type
Employees 18,581

Related